Accessibility Menu
Aethlon Medical logo

Aethlon Medical(NASDAQ) AEMD

Market Cap$8.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-100%
5 Year-100%
1 Year-94%
1 Month-6%
$3.39
+2.35%
+0.08Today
Aethlon Medical last closing stock price
MetricPriceDate
Last closeUSD 3.332026-08-03
Aethlon Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+18.44%USD 2.822026-07-27
1 month-6.1%USD 3.552026-07-02
3 month-71.75%USD 11.802026-05-05
Year to date-75.93%USD 13.852025-12-31
1 year-94.25%USD 58.002025-08-01
3 year-99.76%USD 1,375.602023-08-04
5 year-99.98%USD 22,160.002021-08-04
Since inception-100%USD 4,649,907.001999-03-11

Aethlon Medical Financials at a Glance

Market Cap

$8.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.15M

EPS (TTM)

-$15.88

P/E Ratio

-0.21

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$3.39

Volume

61,931.479

Open

$3.25

Previous Close

$3.33

Daily Range

$3.15 - $3.50

52-Week Range

$2.63 - $137.00

Estimated Earnings Date

Aug 12, 2026

AEMD News

Foolcom-Featured.png

Aethlon Medical Cuts Loss in Fiscal Q1

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aethlon Medical

Aethlon Medical develops devices to filter harmful particles from blood. Its main product helps patients with cancer or severe viral infections. The company aims to support those with limited treatment options.

Gadgets That Filter Trouble: Products and Services

  • Hemopurifier device: Removes viruses and cancer-related particles from blood; company did not recognize revenue during the three months ended June 30, 2025 and remains pre-revenue.
  • Oncology applications: Targets patients with advanced cancers, especially where standard treatments fail.
  • Viral infection focus: Designed for severe viral diseases, including COVID-19, HIV, and hepatitis C.
  • Research collaborations: Works with cancer centers and universities to expand clinical uses.
  • Clinical trials: Conducts early-stage oncology studies in Australia; U.S. viral infection trials have been terminated but an open IDE remains for potential future studies.

Growth Spurts and Strategic Moves

  • Partnered with University of Pittsburgh Medical Center Hillman Cancer Center for head and neck cancer research (2023).
  • Launched phase 1 oncology trial in Australia (2024); three sites open, three patients treated.
  • Discontinued planned clinical trial in India (2024) to focus resources on Australia.
  • Expanded preclinical research into Long COVID and neurological disorders (2025).
  • Received FDA approval for manufacturing at San Diego facility (2025).

What Makes Aethlon Medical Stand Out

Aethlon Medical operates globally through research partnerships and clinical trials. Its Hemopurifier device received "Breakthrough Device" status from the U.S. Food and Drug Administration, highlighting its novel approach. The company focuses on diseases with few existing treatment options, using a unique blood filtration method.

Five Things You Need to Know

  • No revenue reported for Q2 2026 or prior periods; company is pre-revenue.
  • Net loss was $2 million in Q2 2026, improved 48% from Q2 2025.
  • Cash and equivalents were $3 million in Q2 2026, down 61% year-over-year.
  • Operating loss was $1 million in Q2 2026, improved 47% from Q2 2025.

Bottom Line

Aethlon Medical remains focused on developing its Hemopurifier device for critical diseases. The company faces ongoing financial challenges as it advances clinical research without commercial revenue.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

9

CEO

James B. Frakes, MBA

Website

www.aethlonmedical.com

Headquarters

San Diego, CA 92121, US

AEMD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-137.73%

Return on Capital

-139.64%

Return on Assets

-112.92%

Earnings Yield

-4.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.63M

Volume

61.93K

Avg. Volume

133.01K

Financials (TTM)

Gross Profit

-$542.92K

Operating Income

-$7.29M

EBITDA

-$6.65M

Operating Cash Flow

-$7.00M

Capital Expenditure

-$2.06K

Free Cash Flow

-$7.00M

Cash & ST Invst.

$5.03M

Total Debt

$336.72K

Aethlon Medical Performance Analysis

Aethlon Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 574,24595.2%
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Aethlon Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Aethlon Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -468.60-17.0%
20242024-03-31USD -388.68-17.1%
20252025-03-31USD -85.78-77.9%
20262026-03-31USD -10.61-87.6%
Aethlon Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3078.8%
Q22025-09-3056.0%
Q32025-12-3134.5%
Q42026-03-3151.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$79.55K

+5.1%

Gross Margin

0.00%

N/A

Market Cap

$8.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$975.59K

N/A

Employees

9

N/A

Net Income

-$1.88M

+69.9%

EBITDA

-$1.85M

+70.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$5.03M

-8.6%

Total Debt

$336.72K

-48.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$336.72K

+7.6%

Return on Assets

-1.13%

N/A

Return on Invested Capital

-1.49%

N/A

Free Cash Flow

-$1.75M

-4.9%

Operating Cash Flow

-$1.75M

-4.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LNAILunai Bioworks Inc.
$2.39+23.20%
XAIRBeyond Air, Inc.
$6.33+20.00%
VVOSVivos Therapeutics, Inc.
$0.42+2.59%
CODXCo-Diagnostics, Inc.
$1.48+2.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
PLTRPalantir Technologies
$125.65+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.96+0.05%

Questions About AEMD

What is the current price of Aethlon Medical?

Aethlon Medical is trading at $3.33 per share.

What is the 52-week range for Aethlon Medical?

Over the past 52 weeks, Aethlon Medical has traded between $2.63 and $137.00.

How much debt does Aethlon Medical have?

As of the most recent reporting period, Aethlon Medical reported total debt of $514.82K.

How much cash does Aethlon Medical have on hand?

Aethlon Medical reported $5.03M in cash and cash equivalents in its most recent financial results.

What is Aethlon Medical’s dividend yield?

Aethlon Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services